Los Angeles Capital Management LLC Sells 50,284 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Los Angeles Capital Management LLC trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 40.7% during the 4th quarter, Holdings Channel reports. The fund owned 73,117 shares of the biopharmaceutical company’s stock after selling 50,284 shares during the period. Los Angeles Capital Management LLC’s holdings in TG Therapeutics were worth $2,201,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Blue Trust Inc. lifted its position in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the period. Synergy Asset Management LLC bought a new position in TG Therapeutics in the fourth quarter worth approximately $75,000. GAMMA Investing LLC lifted its holdings in TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the period. KBC Group NV boosted its position in TG Therapeutics by 30.5% during the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,092 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at $111,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $28.53 on Friday. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market cap of $4.44 billion, a PE ratio of -285.27 and a beta of 2.26. The business has a 50-day simple moving average of $30.79 and a two-hundred day simple moving average of $27.98.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. StockNews.com cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.